+39 06 99775399 info@reithera.com
Languages
  • Italiano
  • English
  • Home
  • About
  • R&D
  • CMO
  • News
    • Grants
    • Press Release
    • Publications
  • Contact
  • English
    • Italian
An ideal partner for your biotechnological journey An ideal partner for your biotechnological journey
  • Home
  • About
  • R&D
  • CMO
  • News
    • Grants
    • Press Release
    • Publications
  • Contact
  • English
    • Italian

Archives

Monthly Archive for: "June, 2020"
June 2020
0
By ef
In News, Publications
Posted June 23, 2020

MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans

Strategies to enhance the induction of high magnitude T cell responses through vaccination are urgently needed. Major histocompatibility complex (MHC) class II–associated invariant chain (Ii) [...]

READ MORE
0
By ef
In News, Press Release
Posted June 23, 2020

ArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate

Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, [...]

READ MORE
0
By ef
In News, Press Release
Posted June 3, 2020

SGS JOINS FORCES WITH LEADING BIOTECH REITHERA TO FAST-TRACK ITS SINGLE-DOSE COVID-19 VACCINE

SGS has joined forces with leading European biotech company ReiThera to fast-track the development and production of a single-dose COVID-19 vaccine. Italian Biotech ReiThera selected SGS to [...]

READ MORE
Our privacy

Privacy Policy and Cookie Law

Follow us
  • linkedin
  • facebook
  • instagram
  • twitter

ReiThera srl is a biotech company developing products based on gene delivery technologies for advanced therapies, from early development to final QP release.

© Copyright 2018 | Made with by